Compare ARK Genomic Revolution ETF (ARKG) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Kinder Morgan Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.66, while Kinder Morgan Inc trades at $32.14 (market cap $71.46B). The key difference: Kinder Morgan Inc pays a 3.66% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Kinder Morgan Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | KMI | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $43.57 | $34.31 |
52-Week Low | $23.09 | $25.84 |
Market Cap | — | $71.46B |
Enterprise Value | — | $103.34B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Kinder Morgan (KMI) trades at $32.12, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $0.48 EPS, and maintains a solid dividend. Revenue grew to $16.94B in 2025, with net income margin improving to 18.92%. Recent news highlights KMI's exposure to natural gas infrastructure growth and stable cash flows from fee-based contracts.
KMI offers a balanced risk-reward profile with steady cash flow and dividend appeal, supported by a $10.1B project backlog. Risks include commodity price volatility and high debt levels. Analyst consensus is mixed but leans positive, with 47% buy ratings. The stock's valuation at a P/E of 21.56 is reasonable given earnings growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
